These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28315541)

  • 1. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitor therapy-induced hypophysitis ∼ a case series of Taiwanese patients.
    Lin CH; Chen KH; Chen KY; Shih SR; Lu JY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):524-529. PubMed ID: 30104119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.
    Joshi MN; Whitelaw BC; Palomar MT; Wu Y; Carroll PV
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):331-9. PubMed ID: 26998595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
    Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
    Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymphocytic hypophysitis due to ipilimumap therapy].
    Thomsen HH
    Ugeskr Laeger; 2012 Jun; 174(26):1829-30. PubMed ID: 22735122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
    Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
    Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypophysitis on immunotherapy with checkpoint inhibitors.
    Jäger IM; Kohlmann J; Simon JC; Sandner B; Tönjes A; Ziemer M
    J Dtsch Dermatol Ges; 2019 Nov; 17(11):1168-1170. PubMed ID: 31701648
    [No Abstract]   [Full Text] [Related]  

  • 8. [Ipilimumab-induced hypophysitis].
    Schleder S; Schreml S; Heiss P
    Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
    [No Abstract]   [Full Text] [Related]  

  • 9. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
    Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
    Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
    Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
    Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
    Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
    Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case of hypophysitis caused by nivolumab.
    Ishikawa M; Oashi K
    J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
    [No Abstract]   [Full Text] [Related]  

  • 14. Checkpoint Inhibitors: Common Immune-Related Adverse Events and Their Management
.
    Gordon R; Kasler MK; Stasi K; Shames Y; Errante M; Ciccolini K; Skripnik Lucas A; Raasch P; Fischer-Cartlidge E
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):45-52. PubMed ID: 28315555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
    Iwama S; Arima H
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):90-94. PubMed ID: 28603206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
    Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
    Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
    Marlier J; Cocquyt V; Brochez L; Van Belle S; Kruse V
    Endocrine; 2014 Dec; 47(3):878-83. PubMed ID: 24554495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
    Kaehler KC; Egberts F; Lorigan P; Hauschild A
    Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
    Fernandes S; Varlamov EV; McCartney S; Fleseriu M
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
    Bronstein Y; Ng CS; Hwu P; Hwu WJ
    AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.